Kolexia
Poujol Sylvain Pharmacien
Poujol Sylvain
Pharmacien
Icm Montpellier
Montpellier, France
36 Activités
11 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du sein Alopécie Métastase tumorale Adénocarcinome Tumeurs du péritoine Tumeurs du foie Carcinome hépatocellulaire Tumeurs du cerveau

Collaborateurs

Voir plus
Ychou Marc
Ychou Marc
Icm Montpellier, Montpellier, France
Pinguet Frederic
Pinguet Frederic
Icm Montpellier, Montpellier, France
Mazard Thibault
Mazard Thibault
Icm Montpellier, Montpellier, France
Samalin Scalzi Emmanuelle
Samalin Scalzi Emmanuelle
Icm Montpellier, Montpellier, France

Industries

Voir plus
A+A
2 collaboration(s)
Dernière en 2020
MSD
2 collaboration(s)
Dernière en 2022
Sanofi
1 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
NEXIRI: SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.
Essai Clinique (Bayer)   17 juin 2021
Sorafenib alone vs. sorafenib plus GEMOX as 1 -line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.
British journal of cancer   04 avril 2019
A phase I trial assessing oral S-1 combined with fixed doses of irinotecan in advanced gastrointestinal malignancies (aGM) in 1st- or 2nd-line treatment.
2018 ASCO Annual Meeting I   01 juin 2018
Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country.
Journal of pain and symptom management   01 août 2017
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
P-161 A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment
ESMO 17th World Congress on Gastrointestinal Cancer, 1-4 July 2015, Barcelona, Spain   01 juin 2015
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
British journal of cancer   09 janvier 2014
Versatile UCST-based thermoresponsive hydrogels for loco-regional sustained drug delivery.
Journal of controlled release : official journal of the Controlled Release Society   08 novembre 2013
Stability of the ready-to-use solutions of eribulin for intravenous infusion.
Annales pharmaceutiques francaises   17 juillet 2012
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Annals of oncology : official journal of the European Society for Medical Oncology   09 mai 2012